Charles River Laboratories International, Inc. (CRL) and Captain T Cell, a spinoff from Max Delbrück Center in Germany, entered into an agreement on plasmid DNA and retrovirus vector production program. Per the terms of the agreement, Captain T Cell will leverage Charles River’s established plasmid and viral vector contract development and manufacturing organization (“CDMO”) capabilities and get access to advisory services. All of these infrastructures are a part of Charles River’s Cell and Gene Therapy Acc ...